<DOC>
	<DOCNO>NCT01913431</DOCNO>
	<brief_summary>This multicenter , double blind , active-controlled , randomize , parallel group study demonstrate anti-viral activity safety Baracle Tab . Baraclude Tab . patient HBeAg Chronic Hepatitis B . The subject receive two tablet daily 48 day .</brief_summary>
	<brief_title>Baracle Tab . ® Versus Baraclude Tab.® Patients With HBeAg Chronic Hepatitis B</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Entecavir</mesh_term>
	<criteria>Subjects HbeAg Chronic Hepatitis B least six month start Screening visit Subjects HBsAgPositive diagnose screen visit Subjects HBeAgPositive HBeAgnegative diagnose screen visit For diagnosed HBeAgPositive , HBV DNA level equal 1x10^5 copies/ml For diagnosed HBeAgNegative , HBV DNA level equal 1x10^5 copies/ml Subjects NOT administrate antiviral agent include interferon pegylated interferon Subjects HCV , HDV HIV Subjects decompensated liver disease 2.5mg/dl total bilirubin , long 3 second prothrombin time , le 30g/l serum albumin With medical history hemorrhage , hepatic encephalopathy , dyshepatia due ascites , jaundice , varicose vein Less 50ml/min creatinine clearance diagnose screen visit More 50 ng/ml alphafetoprotein screen visit Involved study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2013</verification_date>
</DOC>